Comparative Pharmacology
Head-to-head clinical analysis: APRETUDE versus TIVICAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRETUDE versus TIVICAY.
APRETUDE vs TIVICAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the integration of HIV-1 DNA into host genomic DNA, which is essential for viral replication. It binds to the active site of integrase and blocks the strand transfer step of retroviral DNA integration.
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for HIV replication.
600 mg IM every 2 months, initiated as two consecutive monthly loading doses of 600 mg each, for HIV-1 pre-exposure prophylaxis.
50 mg orally once daily, or 50 mg twice daily when coadministered with potent UGT1A1 inducers (e.g., rifampin). For INSTI-naive patients: 50 mg once daily. For INSTI-experienced patients with suspected resistance: 50 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours following subcutaneous injection, supporting monthly dosing.
Terminal elimination half-life approximately 14 hours (range 11-20 hours) in healthy subjects; supports once-daily dosing with a low pharmacokinetic boost.
Renal (approximately 30% as unchanged drug) and fecal (approximately 50% as metabolites and unchanged drug) following oral administration.
Primarily metabolized by UGT1A1 with minor CYP3A4 contribution; 53% of dose excreted in feces (31% as unchanged drug) and 33% in urine (1% unchanged).
Category C
Category C
Antiretroviral
Antiretroviral, integrase inhibitor